Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited is an Indian research-led pharmaceutical company that develops, manufactures, and markets generic drugs, branded formulations, and active pharmaceutical ingredients (APIs) worldwide. The company structures its operational reporting around Specialty Formulations, Generics, and Active Pharmaceutical Ingredients, focusing on therapeutic areas such as respiratory, dermatology, oncology, and cardiology. Its principal revenue drivers stem from high-volume sales of generic prescription medications, branded formulation sales, active pharmaceutical ingredient delivery, and biopharmaceutical licensing milestone payments. Glenmark Pharmaceuticals holds an established global position in the generic and specialty pharmaceutical industry, maintaining commercial distribution across North America, Europe, India, and Latin America. The enterprise serves hospitals, retail pharmacy networks, healthcare providers, and patients globally. The company focuses on developing complex respiratory generics, advancing novel biological drug candidates through clinical trials, enhancing manufacturing quality standards, and growing specialty product market share. Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India, and its common stock is publicly listed and traded on the National Stock Exchange of India and the BSE.
8 of the funds FundTelligence covers report a position in Glenmark Pharmaceuticals.
- Legal name
- Glenmark Pharmaceuticals Ltd
- Sector
- Health Care
- Country
- India
- Funds holding it
- 8
Funds holding Glenmark Pharmaceuticals
- SEB Asienfond ex Japan — SEB · 0.46 % (full portfolio disclosed, June 2026)
- SEB Emerging Marketsfond — SEB · 0.16 % (full portfolio disclosed, June 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.04 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)
- Storebrand Emerging Markets Plus — Storebrand · 0.03 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- Storebrand Emerging Markets — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Global All Countries — Storebrand · 0.0 % (full portfolio disclosed, October 2026)